摘要
目的:探讨尼洛替尼在伊马替尼不耐受的慢性髓系白血病(CML)患者中的疗效及不良反应。方法:6例伊马替尼耐药的CML患者,其中慢性期5例,进展期1例,持续口服尼洛替尼400mg 2次/d,观察其疗效及不良反应。结果:6例患者平均用药时间为302.5d,5例CML慢性期患者中,3例获得完全细胞遗传学反应,另外2例患者因用药时间分别为15d及25d,故未进行疗效评估;1例急变期患者获得血液学缓解。结论:尼洛替尼对于伊马替尼不耐受的CML患者是有效的,而且耐受性良好,交叉不耐受情况并不常见。
Objective：To observe the efficacy and adverse effects of nilotinib in the treatment of patients with chronic myeloid leukemia（CML） after imatinib intolerance.Method：Six patients with CML after imatinib intolerance,received oral nilotinib at dose of 400mg twice daily.Of them,5 patients were in chronic phase and 1 patient was in blastic phase.Result：The average treatment duration of 6 patients was 302.5 days.In 5 patients with CML in chronic phase,3 patients achieved CCyR.As the other 2 patients had been treated for only 15 days and 25 days respectively,the efficacy was not evaluated.One patient with CML in blastic phase achieved hematological remission.Conclusion：Nilotinib was effective in the treatment of patients with CML after imatinib intolerance,and patients had good tolerance to nilotinib.And the cross-intolerance was not common.
出处
《临床血液学杂志》
CAS
2011年第6期675-678,共4页
Journal of Clinical Hematology
